Annual SG&A
$12.22 M
-$923.00 K-7.02%
31 December 2023
Summary:
Alaunos Therapeutics annual selling, general & administrative expenses is currently $12.22 million, with the most recent change of -$923.00 thousand (-7.02%) on 31 December 2023. During the last 3 years, it has fallen by -$15.45 million (-55.83%). TCRT annual SG&A is now -55.83% below its all-time high of $27.66 million, reached on 31 December 2020.TCRT Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.01 M
+$17.00 K+1.72%
30 September 2024
Summary:
Alaunos Therapeutics quarterly selling, general & administrative expenses is currently $1.01 million, with the most recent change of +$17.00 thousand (+1.72%) on 30 September 2024. Over the past year, it has dropped by -$2.57 million (-71.86%). TCRT quarterly SG&A is now -88.90% below its all-time high of $9.07 million, reached on 30 June 2021.TCRT Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$3.67 B
-$11.78 M-0.32%
30 September 2024
Summary:
Alaunos Therapeutics TTM selling, general & administrative expenses is currently -$3.67 billion, with the most recent change of -$11.78 million (-0.32%) on 30 September 2024. Over the past year, it has dropped by -$3.68 billion (-28973.05%). TCRT TTM SG&A is now -2980011.20% below its all-time high of $34.27 million, reached on 30 September 2021.TCRT TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRT Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.0% | -71.9% | -10000.0% |
| 3 y3 years | -55.8% | -87.7% | -10000.0% |
| 5 y5 years | -38.6% | -79.0% | -10000.0% |
TCRT Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -55.8% | at low | -87.7% | +1.7% | -15.1% | at low |
| 5 y | 5 years | -55.8% | at low | -88.9% | +1.7% | -52.4% | at low |
| alltime | all time | -55.8% | -88.9% | <-9999.0% | at low |
Alaunos Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.01 M(+1.7%) | $6.04 M(-29.9%) |
| June 2024 | - | $990.00 K(-38.8%) | $8.61 M(-19.3%) |
| Mar 2024 | - | $1.62 M(-33.4%) | $10.67 M(-12.7%) |
| Dec 2023 | $12.22 M(-7.0%) | $2.43 M(-32.1%) | $12.22 M(-3.9%) |
| Sept 2023 | - | $3.58 M(+17.5%) | $12.72 M(+2.4%) |
| June 2023 | - | $3.04 M(-3.9%) | $12.42 M(-3.0%) |
| Mar 2023 | - | $3.17 M(+8.3%) | $12.80 M(-2.6%) |
| Dec 2022 | $13.14 M(-52.3%) | $2.92 M(-10.9%) | $13.14 M(+6.7%) |
| Sept 2022 | - | $3.28 M(-4.3%) | $12.31 M(-28.4%) |
| June 2022 | - | $3.43 M(-2.2%) | $17.20 M(-24.7%) |
| Mar 2022 | - | $3.50 M(+67.3%) | $22.84 M(-17.1%) |
| Dec 2021 | $27.56 M(-0.4%) | $2.10 M(-74.4%) | $27.56 M(-19.6%) |
| Sept 2021 | - | $8.17 M(-9.9%) | $34.27 M(+5.6%) |
| June 2021 | - | $9.07 M(+10.2%) | $32.45 M(+8.4%) |
| Mar 2021 | - | $8.23 M(-6.5%) | $29.94 M(+8.2%) |
| Dec 2020 | $27.66 M(+41.7%) | $8.80 M(+38.6%) | $27.66 M(+12.1%) |
| Sept 2020 | - | $6.35 M(-3.1%) | $24.68 M(+6.7%) |
| June 2020 | - | $6.55 M(+10.1%) | $23.14 M(+8.4%) |
| Mar 2020 | - | $5.95 M(+2.3%) | $21.34 M(+9.3%) |
| Dec 2019 | $19.53 M(-2.0%) | $5.82 M(+21.1%) | $19.53 M(+6.9%) |
| Sept 2019 | - | $4.81 M(+1.1%) | $18.27 M(+2.8%) |
| June 2019 | - | $4.75 M(+14.7%) | $17.77 M(-0.7%) |
| Mar 2019 | - | $4.14 M(-9.2%) | $17.90 M(-10.1%) |
| Dec 2018 | $19.92 M(+34.6%) | $4.56 M(+5.9%) | $19.92 M(+3.7%) |
| Sept 2018 | - | $4.31 M(-11.9%) | $19.21 M(+4.0%) |
| June 2018 | - | $4.89 M(-20.6%) | $18.47 M(+6.4%) |
| Mar 2018 | - | $6.16 M(+59.9%) | $17.36 M(+17.3%) |
| Dec 2017 | $14.80 M(+2.9%) | $3.85 M(+7.9%) | $14.80 M(+3.7%) |
| Sept 2017 | - | $3.57 M(-5.5%) | $14.27 M(+0.2%) |
| June 2017 | - | $3.78 M(+5.1%) | $14.23 M(+0.5%) |
| Mar 2017 | - | $3.60 M(+8.3%) | $14.16 M(-1.5%) |
| Dec 2016 | $14.38 M(-18.5%) | $3.32 M(-6.2%) | $14.38 M(+0.4%) |
| Sept 2016 | - | $3.54 M(-4.7%) | $14.32 M(+3.4%) |
| June 2016 | - | $3.71 M(-2.6%) | $13.85 M(-19.5%) |
| Mar 2016 | - | $3.81 M(+16.9%) | $17.21 M(-2.5%) |
| Dec 2015 | $17.65 M(+45.1%) | $3.26 M(+6.3%) | $17.65 M(+2.4%) |
| Sept 2015 | - | $3.06 M(-56.7%) | $17.24 M(+1.3%) |
| June 2015 | - | $7.07 M(+66.4%) | $17.02 M(+31.2%) |
| Mar 2015 | - | $4.25 M(+49.1%) | $12.97 M(+6.6%) |
| Dec 2014 | $12.17 M(-22.3%) | $2.85 M(+0.3%) | $12.17 M(-10.0%) |
| Sept 2014 | - | $2.84 M(-6.2%) | $13.52 M(-1.6%) |
| June 2014 | - | $3.03 M(-11.9%) | $13.74 M(-4.8%) |
| Mar 2014 | - | $3.44 M(-18.1%) | $14.43 M(-7.8%) |
| Dec 2013 | $15.66 M(-19.8%) | $4.20 M(+37.0%) | $15.66 M(+0.9%) |
| Sept 2013 | - | $3.07 M(-17.5%) | $15.52 M(-14.6%) |
| June 2013 | - | $3.72 M(-20.3%) | $18.16 M(-6.1%) |
| Mar 2013 | - | $4.67 M(+15.0%) | $19.35 M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | $19.52 M(+30.3%) | $4.06 M(-28.9%) | $19.52 M(+0.5%) |
| Sept 2012 | - | $5.71 M(+16.5%) | $19.43 M(+11.3%) |
| June 2012 | - | $4.90 M(+1.1%) | $17.46 M(+5.9%) |
| Mar 2012 | - | $4.85 M(+22.2%) | $16.48 M(+10.0%) |
| Dec 2011 | $14.98 M(+28.8%) | $3.97 M(+6.0%) | $14.98 M(+4.5%) |
| Sept 2011 | - | $3.74 M(-4.6%) | $14.34 M(+7.1%) |
| June 2011 | - | $3.92 M(+17.0%) | $13.39 M(+8.3%) |
| Mar 2011 | - | $3.35 M(+0.9%) | $12.36 M(+6.2%) |
| Dec 2010 | $11.64 M(+53.8%) | $3.32 M(+19.1%) | $11.64 M(+4.6%) |
| Sept 2010 | - | $2.79 M(-3.6%) | $11.13 M(+15.0%) |
| June 2010 | - | $2.89 M(+10.0%) | $9.68 M(+14.2%) |
| Mar 2010 | - | $2.63 M(-6.5%) | $8.47 M(+12.0%) |
| Dec 2009 | $7.57 M(-9.6%) | $2.81 M(+110.1%) | $7.57 M(+20.2%) |
| Sept 2009 | - | $1.34 M(-20.9%) | $6.29 M(-6.0%) |
| June 2009 | - | $1.69 M(-1.9%) | $6.70 M(-8.9%) |
| Mar 2009 | - | $1.72 M(+12.0%) | $7.35 M(-12.2%) |
| Dec 2008 | $8.37 M(-12.6%) | $1.54 M(-11.6%) | $8.37 M(-9.8%) |
| Sept 2008 | - | $1.74 M(-25.9%) | $9.28 M(-5.6%) |
| June 2008 | - | $2.35 M(-14.4%) | $9.83 M(-4.8%) |
| Mar 2008 | - | $2.74 M(+12.2%) | $10.33 M(+7.9%) |
| Dec 2007 | $9.58 M(+9.8%) | $2.45 M(+6.7%) | $9.58 M(+0.7%) |
| Sept 2007 | - | $2.29 M(-19.5%) | $9.51 M(+5.1%) |
| June 2007 | - | $2.85 M(+43.1%) | $9.05 M(-1.7%) |
| Mar 2007 | - | $1.99 M(-16.2%) | $9.21 M(+5.6%) |
| Dec 2006 | $8.72 M(+107.9%) | $2.37 M(+29.6%) | $8.72 M(+15.0%) |
| Sept 2006 | - | $1.83 M(-39.1%) | $7.59 M(+4.0%) |
| June 2006 | - | $3.01 M(+100.0%) | $7.29 M(+45.0%) |
| Mar 2006 | - | $1.50 M(+21.4%) | $5.03 M(+20.0%) |
| Dec 2005 | $4.19 M(+17.1%) | $1.24 M(-19.6%) | $4.19 M(+7.8%) |
| Sept 2005 | - | $1.54 M(+106.6%) | $3.89 M(+18.7%) |
| June 2005 | - | $746.20 K(+12.1%) | $3.28 M(+28.7%) |
| Mar 2005 | - | $665.90 K(-28.8%) | $2.55 M(+34.9%) |
| Dec 2004 | $3.58 M(+2130.4%) | $935.90 K(+0.8%) | $1.89 M(+98.4%) |
| Sept 2004 | - | $928.20 K(+5629.6%) | $951.00 K(+4071.1%) |
| June 2004 | - | $16.20 K(+145.5%) | $22.80 K(+245.5%) |
| Mar 2004 | - | $6600.00(>+9900.0%) | $6600.00(>+9900.0%) |
| Dec 2003 | $160.60 K(>+9900.0%) | - | - |
| Dec 2002 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2002 | - | $0.00(0.0%) | $100.00(0.0%) |
| June 2002 | - | $0.00(0.0%) | $100.00(0.0%) |
| Mar 2002 | - | $0.00(-100.0%) | $100.00(0.0%) |
| Dec 2001 | $100.00 | $100.00(>+9900.0%) | $100.00(>+9900.0%) |
| Sept 2001 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2001 | - | $0.00(0.0%) | $8200.00(-50.0%) |
| Mar 2001 | - | $0.00(-100.0%) | $16.40 K(0.0%) |
| Sept 2000 | - | $8200.00(0.0%) | $16.40 K(+100.0%) |
| June 2000 | - | $8200.00 | $8200.00 |
FAQ
- What is Alaunos Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Alaunos Therapeutics?
- What is Alaunos Therapeutics annual SG&A year-on-year change?
- What is Alaunos Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Alaunos Therapeutics?
- What is Alaunos Therapeutics quarterly SG&A year-on-year change?
- What is Alaunos Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Alaunos Therapeutics?
- What is Alaunos Therapeutics TTM SG&A year-on-year change?
What is Alaunos Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of TCRT is $12.22 M
What is the all time high annual SG&A for Alaunos Therapeutics?
Alaunos Therapeutics all-time high annual selling, general & administrative expenses is $27.66 M
What is Alaunos Therapeutics annual SG&A year-on-year change?
Over the past year, TCRT annual selling, general & administrative expenses has changed by -$923.00 K (-7.02%)
What is Alaunos Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of TCRT is $1.01 M
What is the all time high quarterly SG&A for Alaunos Therapeutics?
Alaunos Therapeutics all-time high quarterly selling, general & administrative expenses is $9.07 M
What is Alaunos Therapeutics quarterly SG&A year-on-year change?
Over the past year, TCRT quarterly selling, general & administrative expenses has changed by -$2.57 M (-71.86%)
What is Alaunos Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of TCRT is -$3.67 B
What is the all time high TTM SG&A for Alaunos Therapeutics?
Alaunos Therapeutics all-time high TTM selling, general & administrative expenses is $34.27 M
What is Alaunos Therapeutics TTM SG&A year-on-year change?
Over the past year, TCRT TTM selling, general & administrative expenses has changed by -$3.68 B (-28973.05%)